| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,010,000 |
| Market
Cap: |
172.19(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $4.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 935 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
84,560 |
206,385 |
272,181 |
454,395 |
| Total Sell Value |
$393,343 |
$830,960 |
$965,155 |
$2,986,647 |
| Total People Sold |
6 |
6 |
7 |
9 |
| Total Sell Transactions |
7 |
20 |
25 |
42 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Avagliano Mark |
Chief Business Officer |
• – – |
2024-05-13 |
4 |
S |
$4.79 |
$39,034 |
D/D |
(8,151) |
209,683 |
|
2% |
|
| Perry Andrew |
Chief Commercial Officer |
• – – |
2024-05-13 |
4 |
S |
$4.79 |
$39,034 |
D/D |
(8,151) |
78,951 |
|
2% |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2024-05-13 |
4 |
S |
$4.79 |
$39,034 |
D/D |
(8,151) |
153,245 |
|
2% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2024-05-13 |
4 |
S |
$4.79 |
$39,034 |
D/D |
(8,151) |
161,787 |
|
2% |
|
| Bailey John E. (jack) Jr. |
President and CEO |
• • – |
2024-05-13 |
4 |
S |
$4.79 |
$178,421 |
D/D |
(37,258) |
452,336 |
|
2% |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2024-05-13 |
4 |
S |
$4.79 |
$39,034 |
D/D |
(8,151) |
95,487 |
|
2% |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2024-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
161,396 |
|
- |
|
| Avagliano Mark |
Chief Business Officer |
• – – |
2024-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
217,834 |
|
- |
|
| Thomas Monica R. |
General Counsel |
• – – |
2024-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
115,651 |
|
- |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2024-03-18 |
4 |
S |
$3.02 |
$19,752 |
D/D |
(6,547) |
123,896 |
|
-41% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2024-02-12 |
4 |
AS |
$4.62 |
$132,143 |
D/D |
(28,600) |
169,938 |
|
1% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2024-02-12 |
4 |
OE |
$0.30 |
$8,580 |
D/D |
28,600 |
198,538 |
|
- |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2024-01-04 |
4 |
S |
$2.94 |
$2,121 |
D/D |
(721) |
103,638 |
|
-51% |
|
| Avagliano Mark |
Chief Business Officer |
• – – |
2024-01-04 |
4 |
S |
$2.94 |
$2,121 |
D/D |
(721) |
117,834 |
|
-51% |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
S |
$2.94 |
$327 |
D/D |
(111) |
130,443 |
|
-51% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2024-01-04 |
4 |
S |
$2.94 |
$2,121 |
D/D |
(721) |
169,938 |
|
-51% |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2024-01-03 |
4 |
S |
$3.12 |
$9,416 |
D/D |
(3,019) |
104,359 |
|
-57% |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
37,300 |
107,378 |
|
- |
|
| Thomas Monica R. |
General Counsel |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
27,975 |
78,151 |
|
- |
|
| Avagliano Mark |
Chief Business Officer |
• – – |
2024-01-03 |
4 |
S |
$3.12 |
$10,480 |
D/D |
(3,360) |
118,555 |
|
-57% |
|
| Avagliano Mark |
Chief Business Officer |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
44,760 |
121,915 |
|
- |
|
| Perry Andrew |
Chief Commercial Officer |
• – – |
2024-01-03 |
4 |
S |
$3.12 |
$7,526 |
D/D |
(2,413) |
87,102 |
|
-57% |
|
| Perry Andrew |
Chief Commercial Officer |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
33,570 |
89,515 |
|
- |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2024-01-03 |
4 |
S |
$3.12 |
$1,971 |
D/D |
(632) |
130,554 |
|
-57% |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
37,300 |
131,186 |
|
- |
|
334 Records found
|
|
Page 1 of 14 |
|
|
0.02 (0.44%) 
